Weill Cornell Medicine shared on LinkedIn:
“A new AI-based method shows promise in helping doctors assess the severity of a form of blood cancer called myelodysplastic neoplasms (MDS).
The method compares the physical location, size, and shape of every hematopoietic cell in the patient’s bone marrow sample with those in healthy bone marrow and generates a score that reflects disease severity.
Building on their previous work using AI to develop more detailed images of human bone marrow, Weill Cornell Medicine’s Dr. Sanjay Patel and his collaborator Dr. David Redmond developed a new method using fully deidentified patient samples that may provide more clarity for patients with MDS and their physicians.
The next step will be to validate the tool in larger cohorts of patient samples and determine whether its use improves patient care.
Dr. Patel and Dr. Redmond will team up with colleague Dr. Pinkal Desai to study how the tool performs on samples from patients with other forms of MDS and increasingly recognized precursor conditions.”
Other articles about Weill Cornell Medicine on OncoDaily.